Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.3390/vaccines9050428 http://scihub22266oqcxt.onion/10.3390/vaccines9050428 33923363!8146137!33923363     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Vaccines+(Basel) 2021 ; 9 (5): ä Nephropedia Template TP {{tp|p=33923363|t=2021. Designing a SARS-CoV-2 T-Cell-Inducing Vaccine for High-Risk Patient Groups |pdf=|usr=}}{{33923363}} gab.com Text Designing a SARS-CoV-2 T-Cell-Inducing Vaccine for High-Risk Patient Groups JO: Vaccines (Basel) http://www.kidney.de/pget.php?&tw=1&pmid=33923363 #FOAvip We describe the results of two vaccinations of a self-experimenting healthy volunteer with SARS-CoV-2-derived peptides performed in March and April 2020, respectively. The first set of peptides contained eight peptides predicted to bind to the individual's HLA molecules. The second set consisted of ten peptides predicted to bind promiscuously to several HLA-DR allotypes. The vaccine formulation contained the new TLR 1/2 agonist XS15 and was administered as an emulsion in Montanide as a single subcutaneous injection. Peripheral blood mononuclear cells isolated from blood drawn before and after vaccinations were assessed using Interferon-gamma ELISpot assays and intracellular cytokine staining. We detected vaccine-induced CD4 T cell responses against six out of 11 peptides predicted to bind to HLA-DR after 19 days, following vaccination, for one peptide already at day 12. We used these results to support the design of a T-cell-inducing vaccine for application in high-risk patients, with weakened lymphocyte performance. Meanwhile, an according vaccine, incorporating T cell epitopes predominant in convalescents, is undergoing clinical trial testing. Twit Text FOAVip Designing a SARS-CoV-2 T-Cell-Inducing Vaccine for High-Risk Patient Groups ????Vaccines (Basel) http://www.kidney.de/pget.php?&tw=1&pmid=33923363 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33923363 #FOAvip English Wikipedia <ref>{{Cite pmid|33923363}}</ref> Designing a SARS-CoV-2 T-Cell-Inducing Vaccine for High-Risk Patient Groups #MMPMID33923363 Rammensee HG; Gouttefangeas C; Heidu S; Klein R; Preuss B; Walz JS; Nelde A; Haen SP; Reth M; Yang J; Tabatabai G; Bosmuller H; Hoffmann H; Schindler M; Planz O; Wiesmuller KH; Loffler MW Vaccines (Basel) 2021[Apr]; 9 (5): ä PMID33923363show ga We describe the results of two vaccinations of a self-experimenting healthy volunteer with SARS-CoV-2-derived peptides performed in March and April 2020, respectively. The first set of peptides contained eight peptides predicted to bind to the individual's HLA molecules. The second set consisted of ten peptides predicted to bind promiscuously to several HLA-DR allotypes. The vaccine formulation contained the new TLR 1/2 agonist XS15 and was administered as an emulsion in Montanide as a single subcutaneous injection. Peripheral blood mononuclear cells isolated from blood drawn before and after vaccinations were assessed using Interferon-gamma ELISpot assays and intracellular cytokine staining. We detected vaccine-induced CD4 T cell responses against six out of 11 peptides predicted to bind to HLA-DR after 19 days, following vaccination, for one peptide already at day 12. We used these results to support the design of a T-cell-inducing vaccine for application in high-risk patients, with weakened lymphocyte performance. Meanwhile, an according vaccine, incorporating T cell epitopes predominant in convalescents, is undergoing clinical trial testing. äDesigning a SARS-CoV-2 T-Cell-Inducing Vaccine for High-Risk Patient G(epmc).pdf DeepDyve Pubget Overpricing